Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, A.
Right arrow Articles by Chee Kian, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, A.
Right arrow Articles by Chee Kian, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 13, No. 2, 105-107 (2007)
DOI: 10.1177/1078155207080117

Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures

Alexandre Chan, PharmD, BCPS

Department of Pharmacy, National University of Singapore; Department of Pharmacy, National Cancer Centre, Singapore, phaac{at}nus.edu.sg

Vivianne Shih, BSc Pharm Hons, BCOP

Department of Pharmacy, National Cancer Centre, Singapore

Tham Chee Kian, MBBS, MMed Int Med, MRCP

Department of Medical Oncology, National Cancer Centre, Singapore

Liposomal doxorubicin is becoming popular as a chemotherapeutic agent in the treatment of multiple malignancies. This paper describes an episode of hypersensitivity reaction associated with the infusion of liposomal doxorubicin in an ovarian cancer patient, despite preventive measures being undertaken during her first cycle of chemotherapy. Clinicians may overlook the possibility of hypersensitivity reactions associated with liposomal doxorubicin because routine prophylaxis is not provided and reactions are infrequently observed in practice. Close monitoring during the first 15 min of infusion for signs of hypersensitivity should be mandatory for patients receiving their first dose of liposomal doxorubicin. Further research should identify patients who are at risk of experiencing such hypersensitivity.

Key Words: liposomal doxorubicin • hypersensitivity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?